Internal Reference Number: FOI_7679
Date Request Received: 17/01/2024 00:00:00
Date Request Replied To: 19/01/2024 00:00:00
This response was sent via: By Email
Request Summary: Request on intra-vitreal injections or implants
Request Category: Companies
Question Number 1: I am analysing the usage of intra-vitreal injections or implants by the NHS. I would greatly appreciate if you could answer the following questions: How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from September to December 2023: • Aflibercept • Bevacizumab - Avastin • Bevacizumab - Biosimilar • Brolucizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - Lucentis (pre-filled syringes) • Ranibizumab - Lucentis (vials) • Ranibizumab – Ongavia | |
Answer To Question 1: Aflibercept 1122 Bevacizumab – Avastin 6 Bevacizumab – Biosimilar 0 Brolucizamab 0 Dexamethasone 16 Faricimab 751 Fluocinolone acetonide 0 Ranibizumab - Lucentis (pre-filled syringes) <5 Ranibizumab - Lucentis (vials) 0 Ranibizumab – Ongavia 0 | |
Question Number 2: Please see attached | |
Answer To Question 2: See attached table. To accompany this answer to question 2 please also see the documents listed below: 7679 - Q2 Table Completed.docx | |
Please see Attachments: | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.